title: Long-Term Results of Fludarabine/Melphalan as a Reduced-Intensity Conditioning Regimen in Mantle Cell Lymphoma: The GELTAMO Experience.
abstract: BACKGROUND
  We herein report the long-term results of an allogeneic reduced-intensity conditioning (allo-RIC) protocol used in 21 consecutive patients (16 males, median age 56 years, 71% in complete remission) diagnosed with mantle cell lymphoma (MCL).
  
  
  METHODS
  The allo-RIC consisted of fludarabine plus melphalan and peripheral blood hematopoietic stem cells (PBSCs) from human leukocyte antigen (HLA)-identical siblings were used in all cases. Median CD34+ infused cells was 5.8 times 10(6)/kg. All patients engrafted promptly.
  
  
  RESULTS
  Early toxicity included mild/moderate mucositis (43%), febrile neutropenia (33%) and bacterial infections (19%). With a median follow up of 48 months, four deaths were reported, all due to infections and/or graft-versus-host disease (GVHD), yielding a 3-year cumulative incidence of nonrelapse mortality of 19.5%. Grade III-IV acute GVHD occurred in 15% and chronic GVHD in 78%, being extensive in 39%. The 5-year progression-free survival (PFS) and overall survival (OS) were both 80% (95% CI: 63-97%). Age was the only possible prognostic factor for OS, which was 43% for those aged more than 60 years and 100% for those younger (p < 0.001).
  
  
  CONCLUSIONS
  Our data confirm that allo-RIC offers a low toxicity profile and a chance for prolonged long-term disease-free survival in MCL, particularly in younger patients.
authors.affiliation: Servicio de Hematología, Hospital Santa Creu i Sant Pau, Barcelona, Spain.
authors.forename: Jorge Gayoso
authors.initials: JG
authors.lastname: Cruz
authors.forename: Rodrigo
authors.initials: R
authors.lastname: Martino
authors.forename: Pascual
authors.initials: P
authors.lastname: Balsalobre
authors.forename: Inmaculada
authors.initials: I
authors.lastname: Heras
authors.forename: José Luis
authors.initials: JL
authors.lastname: Piñana
authors.forename: David
authors.initials: D
authors.lastname: Serrano
authors.forename: Javier
authors.initials: J
authors.lastname: de la Serna
authors.forename: José Francisco
authors.initials: JF
authors.lastname: Tomás
authors.forename: Joséa Luis
authors.initials: JL
authors.lastname: Díez-Martíin
authors.forename: Dolores
authors.initials: D
authors.lastname: Caballero
keywords: allogeneic transplantation; mantle cell lymphoma; reduced intensity conditioning
references.citation: Haematologica. 2007 May;92(5):627-34
references.pmid: 17488686
references.citation: Blood. 2004 Dec 1;104(12):3535-42
references.pmid: 15304387
references.citation: J Clin Oncol. 2003 Dec 1;21(23):4407-12
references.pmid: 14645431
references.citation: Ann Oncol. 1999 Nov;10(11):1293-9
references.pmid: 10631455
references.citation: Bone Marrow Transplant. 2003 Apr;31(8):667-78
references.pmid: 12692607
references.citation: Blood. 2008 Oct 1;112(7):2687-93
references.pmid: 18625886
references.citation: Biol Blood Marrow Transplant. 2006 Dec;12(12):1326-34
references.pmid: 17162215
references.citation: Biol Blood Marrow Transplant. 2003 Mar;9(3):162-9
references.pmid: 12652466
references.citation: Blood. 2001 Jun 1;97(11):3390-400
references.pmid: 11369628
references.citation: Blood. 1991 Feb 1;77(3):649-53
references.pmid: 1991174
references.citation: Blood. 2002 Dec 15;100(13):4310-6
references.pmid: 12393626
references.citation: Ann Oncol. 2008 Jun;19 Suppl 4:iv41-4
references.pmid: 18519401
references.citation: Leukemia. 2007 Nov;21(11):2316-23
references.pmid: 17597807
references.citation: Blood. 1996 Jun 1;87(11):4483-94
references.pmid: 8639814
references.citation: Ann Oncol. 2003 May;14(5):737-44
references.pmid: 12702528
references.citation: J Clin Oncol. 2005 Oct 1;23(28):7013-23
references.pmid: 16145068
references.citation: Bone Marrow Transplant. 2005 Jul;36(1):1-17
references.pmid: 15895112
references.citation: J Clin Oncol. 2008 Jan 10;26(2):211-7
references.pmid: 18056679
references.citation: Blood. 2005 Apr 1;105(7):2677-84
references.pmid: 15591112
references.citation: Blood. 2001 Dec 15;98(13):3595-9
references.pmid: 11739162
references.citation: Br J Haematol. 2003 Mar;120(5):793-800
references.pmid: 12614212
references.citation: Blood. 2004 Dec 15;104(13):3865-71
references.pmid: 15304395
references.citation: Bone Marrow Transplant. 2000 May;25(10):1021-8
references.pmid: 10828860
references.citation: J Clin Oncol. 2005 Mar 20;23(9):1984-92
references.pmid: 15668467